Types of Immunotherapy for Metastatic Bladder Cancer

Your immune system is designed to fight infection and diseases, including cancer. But cancer cells can grow unchecked because they avoid your body’s defenses.

Immunotherapy drugs work by making cancer cells easier targets or by boosting the immune system to make it more effective against the disease.

There are now several immunotherapy drugs used to treat metastatic bladder cancer.  These drugs are called checkpoint inhibitors. To keep your immune system from attacking normal cells, your body uses proteins called checkpoints. They help the immune system tell if other cells are a normal part of your body and should be left alone or invaders that should be attacked.

Cancer cells can trick your immune system by binding to the cells that are supposed to fight it. When that happens, the checkpoint signals your body not to attack. A checkpoint inhibitor stops these cells from binding. That way, your immune system recognizes and targets the cancer.

The FDA has approved several checkpoint inhibitor drugs for advanced bladder cancer that has gotten worse during of after chemotherapy. These include:

These drugs are given every 2-3 weeks by infusion, which means through a tube (an IV) that goes into a vein.                                         

One benefit of immunotherapy is it uses your body’s natural defenses. Once your immune system better recognizes cancer, it can continue to target those cells even if you’re treatment has ended.

Other Immunotherapies for Bladder Cancer

Researchers are now testing other potential immunotherapy drugs to see how well they work on their own and combined with other treatments.

Researchers are also testing combinations of immunotherapies. Early results showed that nivolumab combined with another drug, ipilimumab, worked in 26% to 38% of people who took them.

Researchers are also studying atezolizumab in combination with another check-point inhibitor called MTIG7192A.

WebMD Medical Reference Reviewed by Laura J. Martin, MD on March 03, 2019



National Cancer Institute: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy.”

Memorial Sloan Kettering Cancer Center: “Immunotherapy,” “FDA Approves ‘Game Changer’ Immunotherapy Drug for Bladder Cancer,” “A Phase II Study Assessing Mediators of Response to Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Melanoma or Bladder Cancer,” A Phase I/IB Study of Immunotherapy with CPI-444 Alone and with Atezolizumab in Patients with Metastatic Solid Tumors.”

American Cancer Society: “FDA Approves New Immunotherapy Drug for Bladder Cancer,” “Immunotherapy for bladder cancer.”

The University of Texas MD Anderson Cancer Center: “Q&A Understanding Immunotherapy,” “Nivolumab immunotherapy helps patients with advanced bladder cancer,” “Immune checkpoint inhibitors shrink tumors in 26 to 38 percent of metastatic bladder cancer patients.”

American Society of Clinical Oncology: “Patients With Advanced Bladder Cancer Benefit From Anti-PD-L1 Immunotherapy.”

The Lancet: “Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.”

FDA: “Nivolumab for Treatment of Urothelial Carcinoma.”

© 2019 WebMD, LLC. All rights reserved.